影像模态与寡转移去势抵抗性前列腺癌转移灶定向治疗结局:PRECISE-MDT队列更新分析
该研究在PRECISE-MDT队列中新增27例后共分析102例寡转移去势抵抗性前列腺癌患者,比较PSMA PET/CT、胆碱PET/CT和常规影像引导的转移灶定向治疗。经逆概率治疗加权调整后,PSMA PET/CT引导者生化无复发生存优于胆碱PET/CT和常规影像,总生存优于常规影像。
要点
- PSMA PET/CT引导MDT的生化无复发生存优于胆碱PET/CT和常规影像。
- PSMA PET/CT引导MDT的总生存优于常规影像引导。
- 结果支持PSMA PET/CT在omCRPC的MDT规划中具有治疗相关性。
核心结论
- PSMA PET/CT引导的MDT与改善的临床结局相关,支持其在omCRPC的MDT规划中具有治疗相关性。
研究设计与样本
- 对PRECISE-MDT队列进行更新分析,在原队列基础上新增27例,共纳入102例omCRPC患者。
- 比较PSMA PET/CT、胆碱PET/CT和常规影像引导的MDT,主要终点为经逆概率治疗加权调整后的生化无复发生存和总生存。
主要发现
- 常规影像引导20例(19.6%),胆碱PET/CT引导56例(54.9%),PSMA PET/CT引导26例(25.5%)。
- PSMA PET/CT引导者生化无复发生存优于胆碱PET/CT(中位未达到[NR] vs. 11.7个月,P=0.031)。
- PSMA PET/CT引导者生化无复发生存优于常规影像(NR vs. 7.1个月,P=0.002)。
- PSMA PET/CT引导者总生存优于常规影像(NR vs. 46.0个月,P=0.036)。
临床怎么用
- 在omCRPC患者规划MDT时,可优先考虑以PSMA PET/CT作为引导影像以改善临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
It is unclear whether the imaging modality used to guide metastasis-directed therapy (MDT) influences outcomes in oligometastatic castration-resistant prostate cancer (omCRPC). Methods: We performed an updated analysis of the PRECISE-MDT cohort, adding 27 patients to the original cohort. MDT guided by prostate-specific membrane antigen (PSMA) PET/CT, choline PET/CT, and conventional imaging was compared in 102 patients with omCRPC. The primary outcomes were biochemical recurrence-free survival and overall survival after adjustment for inverse probability of treatment weighting. Results: MDT was guided by conventional imaging in 20 (19.6%) patients, choline PET/CT in 56 (54.9%) patients, and PSMA PET/CT in 26 (25.5%) patients. PSMA PET/CT guidance yielded longer biochemical recurrence-free survival than did choline PET/CT (median not reached [NR] vs. 11.7 mo, P = 0.031) and conventional imaging (NR vs. 7.1 mo, P = 0.002). Overall survival favored PSMA PET/CT versus conventional imaging (NR vs. 46.0 mo, P = 0.036). Conclusion: PSMA PET/CT guidance was associated with improved clinical outcome, supporting its therapeutic relevance for MDT planning in omCRPC.
引用
- Bauckneht M, Belgioia L, Albano D, et al. Imaging Modality and Outcomes of Metastasis-Directed Therapy in Oligometastatic Castration-Resistant Prostate Cancer: An Updated Analysis of the PRECISE-MDT Cohort. J Nucl Med. 2026. PMID: 42276786. doi:10.2967/jnumed.125.271680
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。